lanthanum has been researched along with Hyperphosphatemia in 160 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (20.00) | 29.6817 |
| 2010's | 106 (66.25) | 24.3611 |
| 2020's | 22 (13.75) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, A; Xu, G; Zhao, L | 1 |
| Badve, SV; Block, GA; Elder, GJ; Hawley, CM; Johnson, DW; Lioufas, NM; Pascoe, EM; Toussaint, ND | 1 |
| Achenbach, H; Murray, RA; Shavkin, A; Sundberg, A; Szabó, T; Uddin, S; Umeh, O; Vergani, A; Wasilewska, A | 1 |
| Fukui, K; Gao, J; Hashimoto, A; Kanome, Y; Kohno, M; Nakatsu, M; Ogawa, Y | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Dooley, JW; Hack, M; Rappaport, SH; Shah, T; Vineyard, T | 1 |
| Gupta, P; Jermasek, D; Reddy, G; Sprague, SM | 1 |
| Chang, X; Li, M; Shang, S; Xu, W; Yu, M; Zhou, Q | 1 |
| Kano, M; Katoh, M; Okabe, T; Okazaki, R; Tanaka, Y; Toyoda, H; Ueno, M | 1 |
| Fan, GQ; Fu, X; Liang, QR; Luo, RG; Tang, Q; Zhao, J | 1 |
| Kametani, K; Ota, H; Oyama, T; Shimoda, T; Shiozawa, S; Takahashi, A; Tomori, A; Yamada, T | 1 |
| Floege, J | 2 |
| Fujikawa, K; Hiroyoshi, T; Isoyama, N; Kuro-O, M; Matsuyama, H; Miura, Y; Nagata, Y; Nakamura, K | 1 |
| Block, GA; Chertow, GM; Chonchol, M; de Boer, IH; Ginsberg, C; Hoofnagle, A; Kestenbaum, B; Zelnick, LR | 1 |
| Iwamuro, M; Okada, H; Tanaka, T; Urata, H | 2 |
| Jiang, M; Wan, T; Wang, Y; Xu, C; Zheng, H | 1 |
| Gräfe, JL; Nguyen, J; Pejović-Milić, A | 1 |
| Badve, SV; Block, GA; Boudville, N; Cameron, JD; Campbell, KL; Chen, SSM; Elder, GJ; Faull, RJ; Hawley, CM; Holt, SG; Hooi, LS; Jackson, D; Jardine, MJ; Johnson, DW; Kerr, PG; Lau, KK; Lioufas, NM; Narayan, O; Pascoe, EM; Pedagogos, E; Perkovic, V; Polkinghorne, KR; Pollock, CA; Reidlinger, D; Robison, L; Smith, ER; Toussaint, ND; Valks, A; Walker, RJ; Wang, AYM | 1 |
| Acedo, IE; de la Mata, DM; Díaz, CC; Irurita, VJ; San Martín, LZ; Santos, ÁP | 1 |
| Wald, R; Walsh, MW | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Koiwa, F; Sakaguchi, Y; Tanaka, R; Tatsugami, F; Teramukai, S; Tomiyama, N; Tsujimoto, Y | 1 |
| Akizawa, T; Fukagawa, M; Fukushima, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Fujimoto, D; Miyagi, A; Miyagi, J; Ogawa, H; Okushi, S; Takahashi, S; Tamura, U; Tanahashi, T | 1 |
| Cardone, KE; Hudson, JQ; St. Peter, WL; Wazny, LD; Weinhandl, E | 1 |
| Abe, T; Arakane, M; Daa, T; Etoh, T; Gamachi, A; Inomata, M; Kondo, Y; Kusaba, T; Murakami, K; Nagai, T; Nishida, H; Shiraishi, N; Shitomi, Y; Yano, S; Yokoyama, S | 1 |
| Iwamuro, M; Murakami, N; Nasu, J; Nose, S; Okada, H; Shiode, J; Yamamoto, K; Yoshioka, M | 1 |
| Amari, Y; Hattori, K; Hirose, Y; Imanishi, M; Maeda, T; Moriya, T; Nishida, S; Sakaguchi, M | 1 |
| St Peter, WL; Wazny, LD; Weinhandl, ED | 1 |
| Garg, AX; Habbous, S; Martin, J; Przech, S; Sarma, S | 1 |
| Li, H; Lu, X; Wang, F; Wang, S; Xiong, R; Zhang, J | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Wada, T | 1 |
| Carfagna, F; Del Vecchio, L; Locatelli, F; Pontoriero, G | 1 |
| Gao, Y; Li, Y; Lv, C; Wang, G; Wang, Z | 1 |
| Petrou, P | 1 |
| Bhargava, R; Brenchley, P; Hann, M; Hurst, H; Hutchison, AJ; Kalra, PA | 1 |
| Badve, SV; Elder, G; Hawley, C; Lioufas, N; Pascoe, E; Pedagogos, E; Toussaint, ND; Valks, A | 1 |
| Li, G; Liu, D; Ma, Z; Miao, X; Wu, Y; Xing, H; Yu, T; Zhang, X | 1 |
| Awad, C; Gilkison, K; Shaw, E | 1 |
| Badve, SV; Toussaint, ND; Yeung, WG | 1 |
| Black, T; Burbridge, R; Philips, G | 1 |
| Copley, JB; Gill, M; Hutchison, AJ; Poole, L; Wilson, RJ | 1 |
| Ando, R; Chida, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohtsuka, M; Sato, H; Tachibana, K; Takayama, M; Yamada, K; Yoshizaki, Y | 1 |
| Furui, H; Gotoh, J; Hattori, M; Horie, T; Iida, J; Kawamura, A; Kukita, K; Meguro, J; Onodera, K; Tamaki, T; Tsuchihashi, S; Yonekawa, M | 1 |
| Hasegawa, Y; Kamo, Y; Kikuchi, N; Matsuda, E; Sekino, H; Sekino, M; Takeuchi, K | 1 |
| Hong, Z; Ishizu, T; Kaneko, Y; Matsunaga, T; Taru, Y | 1 |
| Inaba, M; Ito, A; Nitta, K; Otsubo, S; Satoh, S; Tanaka, M; Tominaga, Y; Yajima, A | 1 |
| Kabaya, T; Mitsuhashi, T; Miyajima, S; Nitta, K; Ogawa, T; Ohba, T; Otsuka, K; Shizuku, J; Takahashi, M; Takahashi, N; Yamashita, T | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Kondo, F; Kumata, C; Mizobuchi, M; Ogata, H; Ono, N; Uda, S; Yamazaki-Nakazawa, A | 1 |
| Guo, H; Tang, S; Zhang, S; Zhang, X | 1 |
| Elisaf, MS; Kalaitzidis, RG | 1 |
| Baldischweiler, J; Imanidis, G; Kriwet, B; Lanz, M; Schill, J; Stafford, J | 1 |
| Akhtar, J; Chen, B; Wang, H; Wang, R; Yu, C; Zhang, H; Zhao, T | 1 |
| Di, B; Gao, X; Huang, W; Liu, J; Tang, Y; Zhang, F | 1 |
| Goumenos, DS; Papachristou, E; Sonikian, M | 1 |
| Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG | 1 |
| Del Vecchio, L; Locatelli, F | 1 |
| Copley, JB; Keith, MS; Preston, P; Wilson, RJ | 2 |
| Akhtar, J; Bing, C; Che, Y; Kezhou, Y; Rong, W; Tingting, Z | 1 |
| Galani, VJ; Prajapati, VA; Shah, PR | 1 |
| Cannata-Andía, J; González, MT; González-Parra, E; Torregrosa, JV | 1 |
| Ando, R; Chida, Y; Inagaki, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohnishi, T; Ohtsuka, M; Tachibana, K; Takayama, M; Yama, S; Yamada, K | 1 |
| Hara, K; Kishi, Y; Kurosawa, N; Obara, Y; Takada, D; Yamashiro, H | 1 |
| Haruhara, K; Kamejima, S; Kanzaki, G; Mafune, H; Manabe, M; Mashiko, H; Okamoto, H; Yokoo, T | 1 |
| Kumagai, J; Mukai, I; Takahashi, N; Tsuchiya, S; Yoshizawa, T | 1 |
| Matsuda, Y; Shigematsu, T; Takahara, Y; Takahashi, S | 1 |
| Brunelli, SM; Copley, JB; Keith, MS; Sibbel, S; Wilson, RJ | 1 |
| Kawaguchi, K; Kodama, R; Makino, M; Nagasawa, M; Nakamura, H; Shimojo, H | 1 |
| Block, G; Isakova, T | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Suzuki, H | 1 |
| D'Haese, PC; Robijn, S; Verhulst, A; Vervaet, BA | 1 |
| Matsumura, K | 1 |
| Hanafusa, N | 1 |
| Suzuki, H; Takenaka, T; Yamanaka, T; Yoshida, M | 1 |
| Beaubien-Souligny, W; Bell, R; Bezzaoucha, S; Lafrance, JP; Lamarche, C; Ouimet, D; Pichette, V; Vallee, M | 1 |
| Iwatani, Y; Masumoto, AR; Mima, T; Moribata, MK; Nakashima, YM; Negi, S; Ohya, M; Shigematsu, T; Tatsuta, K; Yamanaka, S | 1 |
| Lederer, SR; Schmid, H | 1 |
| Haratake, J; Ohtani, A; Yasunaga, C | 1 |
| Iwamuro, M; Okada, H; Sakae, H | 1 |
| Kobayashi, M; Maruyama, I; Maruyama, K; Tatemichi, S; Yaguchi, A; Yonekubo, S | 1 |
| Gutekunst, L | 1 |
| Iwamuro, M; Kimoto, K; Okada, H; Tanaka, T; Urata, H | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Kaneda, H; Ogata, H | 1 |
| Copley, JB; Garafola, S; Hutchison, AJ; Wilson, RJ | 1 |
| Acedillo, R; Garg, AX; Habbous, S; Martin, J; Przech, S; Sarma, S | 1 |
| Abraham, JL; Everett, JM; Hoda, RS; Hundemer, GL; Lauwers, GY; Misdraji, J; Sanyal, S; Tolkoff-Rubin, N; Yee, E | 1 |
| Ando, A; Iwamuro, M; Kimura, K; Kusumoto, C; Nada, T; Okada, H; Otsuka, F; Tanaka, T; Urata, H; Yamauchi, K | 1 |
| Hutchison, AJ; Laville, M | 1 |
| Anger, M; Fishbane, S; Martin, KJ; Mehrotra, R; Sprague, SM; Zeig, S | 1 |
| Barnett, ME; Hutchison, AJ; Krause, R; Kwan, JT; Siami, GA | 1 |
| Damment, SJ; Pennick, M | 1 |
| Rodríguez Portillo, M | 1 |
| Torregrosa Prats, V | 1 |
| Valdivieso, JM | 1 |
| Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM | 1 |
| Shigematsu, T | 3 |
| Abboud, H; Dauphin, M; Finn, W; Qiu, P; Sprague, SM; Zhang, P | 1 |
| Chen, B; D'Haese, PC; Dams, G; De Broe, ME; De Clerck, N; Neven, E; Persy, V; Postnov, A | 1 |
| Koiwa, F; Sato, Y | 1 |
| Joki, N | 1 |
| Shigematsu, T; Tatsuta, K | 1 |
| Kazama, JJ | 1 |
| Taniguchi, M | 1 |
| Kadowaki, D; Maruyama, T | 1 |
| Hutchison, AJ; Mohammed, I | 1 |
| Barton Pai, A; Conner, TA; McQuade, CR | 1 |
| Negi, S; Oda, H; Ohura, M; Sakaguchi, T; Shigematsu, T | 1 |
| Hutchison, AJ | 1 |
| Connor, A; Taylor, JE | 1 |
| Ketteler, M | 1 |
| Shigematsu, T; Skaguchi, T | 1 |
| Craig, JC; Elder, GJ; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Kurz, B; Müller, GA | 1 |
| Pratt, R; Smyth, M; Wilson, R; Zhang, P | 1 |
| Rees, L; Shroff, RC | 1 |
| Borrows, R; Chan, WL; Chapman, E; Collings, K; Dale, C; De Waal, S; Moore, J; Patel, V; Rounsley, K; Tanner, J; Turner, E | 1 |
| Manns, B; Pannu, N; Tonelli, M | 1 |
| Alonso Alvarez, MA; Díez Ojeda, B; Medrano Martínez, S | 1 |
| Auchère, D; Beaune, P; Benchitrit, J; Drüeke, TB; Flinois, JP; Joki, N; Lacour, B; Nikolov, IG; Patey, N; Vicca, S; Ziol, M | 1 |
| Hayashi, H; Kiriyama, T; Kumita, S; Machida, M; Sekine, T; Yamaguchi, H | 1 |
| Blanco Rodríguez, I; Pobes Martínez de Salinas, A; Quiñones Ortiz, L; Suárez Laurés, A | 1 |
| Negi, S; Shigematsu, T | 2 |
| Chacko, Y; Clark, CJ | 1 |
| Buscombe, J; Davenport, A; Fürstenberg, A | 1 |
| Almirall, J; Betancourt, L; Calvet, X; Esteve, V; López, T; Martínez-Ocaña, JC; Ruiz, A; Valenzuela, MP | 1 |
| Laville, M | 1 |
| Damment, SJ | 1 |
| Arisaka, H; Nakaoka, A; Shigematsu, T; Tokumoto, A | 1 |
| Fujii, H; Fujimori, A; Fukagawa, M; Goto, S; Hasegawa, H; Kamae, I; Kim, JI; Komaba, H; Moriwaki, K; Nishi, S; Nishioka, M; Shibuya, K; Shin, J; Taniguchi, M; Yoshiya, K | 1 |
| Campbell, SB; Hawley, CM; Isbel, NM; Johnson, DW; Mudge, DW; Petrie, JJ; van Eps, CL | 1 |
| Brenchley, PE; Hutchison, AJ; Smith, CP | 1 |
| Matalon, A; Michelis, MF; Vemuri, N | 1 |
| Brunner-Ziegler, S; Fröschl, B; Hiebinger, C; Zsifkovits, J | 1 |
| Moe, SM; Moorthi, RN | 1 |
| Akehurst, R; Goldsmith, D; Hodgkins, P; Keith, MS; Park, H; Rascati, KL; Smyth, M | 1 |
| Bonofiglio, R; Coppolino, G; Greco, R; Lofaro, D; Papalia, T; Senatore, M | 1 |
| Dennis, K; Pennick, M; Poole, L; Smyth, M | 1 |
| Bull, MD; Mulgrew, CJ; Shrimanker, R; Thomas, MR | 1 |
| Basterrechea, M; de Arriba, G; Gómez, L; Hernández, B; Pérez, K; Rodríguez-Palomares, JR; Tallón, S | 1 |
| Bover, J; Brenna, I; Ciceri, P; Cozzolino, M; Cusi, D; Elli, F; Gallieni, M; Rizzo, MA; Stucchi, A | 1 |
| Keith, MS; Lok, CE; Morton, AR; Soroka, SD; Tolley, K; Vegter, S | 1 |
| Hanba, Y; Masumoto, A; Moribata, M; Shigemathu, T | 1 |
| Drüeke, TB; Massy, ZA | 1 |
| Kasai, S; Kinoshita, Y; Murata, Y; Sato, K | 1 |
| Allison, MA; Asplin, J; Block, GA; Chertow, GM; Hoofnagle, AN; Kestenbaum, B; Ketteler, M; Kooienga, L; Mannstadt, M; Persky, MS; Smits, G; Spiegel, DM; Thadhani, R; Wheeler, DC; Wolf, M | 1 |
| Ginard-Vicens, D; Gomila-Roy, GE; Hemfelt-Minobis, A; Khorrami-Minaei, S; Vila-Navarro, S | 1 |
| Chiyotanda, S; Fujimoto, S; Fukudome, K; Kitamura, K; Sato, Y; Toida, T; Yamada, K | 1 |
| Eriguchi, M; Kitazono, T; Nakano, T; Tanaka, S; Taniguchi, M; Tsuruya, K; Yamada, S; Yoshida, H | 1 |
| Evenepoel, P; Meijers, B | 1 |
| Choi, HY; Lee, HY; Lee, YK; Shin, SK | 1 |
| Chen, JH; Chen, XM; Ding, GH; Fan, YP; Liu, ZH; Mei, CL; Ni, ZH; Wang, LN; Wang, M; Xu, J; Yu, XQ; Yuan, FH; Zhang, AP; Zhang, YX | 1 |
| Sprague, SM | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
| Brancaccio, D; Cozzolino, M | 1 |
| Daem, AO; Lefèbvre, D; Lemaitre, V; Vrigneaud, L | 1 |
50 review(s) available for lanthanum and Hyperphosphatemia
| Article | Year |
|---|---|
Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperphosphatemia; Lanthanum; Observational Studies as Topic; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer; Treatment Outcome | 2021 |
Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
Topics: Chelating Agents; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2022 |
Distribution of lanthanum carbonate in the gastric mucosa confirmed by electron microscopy with a magnified endoscopy: a case report and literature review.
Topics: Aged; Gastric Mucosa; Gastroscopy; Humans; Hyperphosphatemia; Lanthanum; Male; Microscopy, Electron, Scanning; Renal Dialysis | 2020 |
Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
Topics: Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer | 2020 |
Review of the diagnosis of gastrointestinal lanthanum deposition.
Topics: Atrophy; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum | 2020 |
Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide.
Topics: Calcium; Humans; Hydroxides; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2020 |
Early gastric cancer with lanthanum deposition mucosa by endoscopic submucosal dissection: a case report and literature review.
Topics: Endoscopic Mucosal Resection; Gastric Mucosa; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Stomach Neoplasms | 2021 |
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
Topics: Calcium Compounds; Chelating Agents; Drug Costs; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Meta-Analysis as Topic; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2017 |
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Topics: Adult; Aged; Calcium Carbonate; Chelating Agents; Cost-Benefit Analysis; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer | 2018 |
Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
Topics: Calcium; Cardiovascular Diseases; Humans; Hyperphosphatemia; Lanthanum; Mortality; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2018 |
Current and potential treatment options for hyperphosphatemia.
Topics: Animals; Chelating Agents; Drug Design; Humans; Hyperphosphatemia; Iron; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2018 |
A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
Topics: Chelating Agents; Cost-Benefit Analysis; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Life Expectancy; Renal Dialysis; Sevelamer | 2019 |
Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
Topics: Bone and Bones; Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Parathyroid Hormone; Phosphates; Vascular Calcification | 2013 |
Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
Topics: Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Placebos; Renal Dialysis; Treatment Outcome | 2014 |
Optimal use of phosphate binders in chronic kidney disease.
Topics: Aluminum Hydroxide; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Magnesium; Patient Compliance; Phosphates; Polyamines; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2013 |
Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Topics: Calcium; Calcium, Dietary; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Naphthalenes; Phosphorus; Phosphorus, Dietary; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
[Iron, aluminum, and lanthanum-based drugs for treatment of hyperphosphatemia].
Topics: Aluminum Compounds; Clinical Trials as Topic; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Iron Compounds; Lanthanum | 2015 |
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Topics: Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Drug Discovery; Humans; Hyperphosphatemia; Japan; Lanthanum; Polyamines; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2015 |
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Topics: Animals; Carbonates; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Lanthanum; Magnesium; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Starch; Sucrose | 2015 |
Phosphate binders in chronic kidney disease: a systematic review of recent data.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
An Update on Phosphate Binders: A Dietitian's Perspective.
Topics: Aluminum Hydroxide; Calcium Carbonate; Diet; Dose-Response Relationship, Drug; Humans; Hyperphosphatemia; Lanthanum; Nutritionists; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
Lanthanum carbonate: safety data after 10 years.
Topics: Adult; Aged; Animals; Biomarkers; Chelating Agents; Clinical Trials, Phase IV as Topic; Databases, Factual; Female; Humans; Hyperphosphatemia; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Safety; Phosphates; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Topics: Biomarkers; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Safety; Sevelamer; Treatment Outcome | 2017 |
Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
Topics: Animals; Biological Availability; Clinical Trials as Topic; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Tissue Distribution | 2008 |
[Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
Topics: Animals; Bone and Bones; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyperphosphatemia; Intestinal Absorption; Kidney Failure, Chronic; Lanthanum; Liver; Nervous System; Phosphorus; Rats; Tissue Distribution | 2008 |
[Lanthanum carbonate in clinical practice].
Topics: Administration, Oral; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Gastrointestinal Diseases; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Tablets | 2008 |
[Experimental advances in mineral metabolism].
Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins | 2008 |
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency | 2008 |
[Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
Topics: Administration, Oral; Aluminum Compounds; Calcium Carbonate; Chronic Disease; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2009 |
[Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Tissue Distribution | 2009 |
[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Randomized Controlled Trials as Topic | 2009 |
[Is lanthanum carbonate a safe drug?].
Topics: Administration, Oral; Chronic Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum | 2009 |
[Use of phosphate binder in predialysis patients].
Topics: Calcium Carbonate; Chronic Disease; Dialysis; Drug Approval; Humans; Hyperphosphatemia; Japan; Kidney Diseases; Lanthanum; Polyamines; Prognosis; Sevelamer | 2009 |
[To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].
Topics: Chronic Disease; Drug Administration Schedule; Hyperphosphatemia; Kidney Diseases; Lanthanum; Patient Compliance; Patient Education as Topic; Polyamines; Sevelamer | 2009 |
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Topics: Acetates; Administration, Oral; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Drug Monitoring; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Magnesium; Nephrology; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
Therapeutic use of the phosphate binder lanthanum carbonate.
Topics: Bone and Bones; Clinical Trials as Topic; Cognition; Humans; Hyperphosphatemia; Lanthanum; Liver; Phosphates | 2009 |
[Advances in blood purification medicine in 2008].
Topics: Anemia; Hematinics; Hemofiltration; Hepatitis C; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Plasma Exchange; Practice Guidelines as Topic; Renal Dialysis | 2009 |
Oral phosphate binders.
Topics: Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer | 2009 |
The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
Topics: Chelating Agents; Chronic Disease; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Polyamines; Renal Dialysis; Sevelamer | 2009 |
[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
Topics: Acetates; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Chelating Agents; Drug Design; Gels; Humans; Hyperphosphatemia; Lanthanum; Macromolecular Substances; Phosphorus, Dietary; Polyamines; Polymers; Renal Dialysis; Sevelamer | 2009 |
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Topics: Acetates; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hypercalcemia; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Sevelamer | 2009 |
Phosphate binders in CKD: chalking out the differences.
Topics: Calcium; Calcium Carbonate; Child; Diet; Humans; Hyperparathyroidism; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2010 |
Oral phosphate binders in patients with kidney failure.
Topics: Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Topics: Cardiovascular Diseases; Chronic Disease; Drug Design; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Risk | 2010 |
[Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
Topics: Humans; Hyperphosphatemia; Lanthanum; Renal Insufficiency, Chronic | 2011 |
Pharmacology, efficacy and safety of oral phosphate binders.
Topics: Acetates; Animals; Calcium Compounds; Chelating Agents; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Intestinal Absorption; Kidney Failure, Chronic; Kidney Tubules, Proximal; Lanthanum; Parathyroid Hormone; Phosphates; Polyamines; Renal Dialysis; Sevelamer | 2011 |
Phosphate control in peritoneal dialysis.
Topics: Calcium; Humans; Hyperphosphatemia; Lanthanum; Peritoneal Dialysis; Phosphates | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Topics: Aluminum Hydroxide; Calcium Carbonate; Chelating Agents; Cholestyramine Resin; Chronic Disease; Diet, Protein-Restricted; Drug Design; Humans; Hyperphosphatemia; Ion Exchange Resins; Kidney Diseases; Lanthanum; Phosphorus, Dietary; Polyamines; Sevelamer | 2012 |
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Topics: Calcium; Chelating Agents; Clinical Trials as Topic; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer; Treatment Outcome | 2007 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
39 trial(s) available for lanthanum and Hyperphosphatemia
| Article | Year |
|---|---|
An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis.
Topics: Adolescent; Child; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2022 |
Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial.
Topics: Calcium; Calcium Carbonate; Chelating Agents; Coronary Artery Disease; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Dialysis; Treatment Outcome; Vascular Calcification | 2022 |
The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Calcium; Calcium Carbonate; Drug Substitution; Female; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Prospective Studies; Renal Dialysis | 2020 |
Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
Topics: Acetates; Aged; Calcium Compounds; Chelating Agents; Double-Blind Method; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2020 |
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Topics: Aged; Aorta, Abdominal; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pulse Wave Analysis; Renal Insufficiency, Chronic; Tomography, X-Ray Computed; Vascular Calcification | 2020 |
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Topics: Adult; Aged; Calcinosis; Coronary Artery Disease; Disease Progression; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Sequestering Agents; Sucrose; Young Adult | 2021 |
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Topics: Aged; Calcium Carbonate; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Hip Fractures; Humans; Hyperparathyroidism; Hyperphosphatemia; Incidence; Japan; Lanthanum; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis; Vascular Calcification | 2021 |
Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Calcium Carbonate; Charcoal; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vascular Calcification | 2019 |
A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
Topics: Aged; Cardiovascular Diseases; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Patient Acceptance of Health Care; Patient Dropouts; Phosphates; Phosphorus, Dietary; Renal Dialysis; Sepsis; Sevelamer | 2019 |
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Topics: Adult; Cardiovascular Diseases; Clinical Protocols; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic | 2019 |
Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
Topics: Double-Blind Method; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Peritoneal Dialysis; Placebo Effect; Treatment Outcome | 2013 |
Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
Topics: Aged; Calcium; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Dialysis; Time Factors; Treatment Outcome | 2013 |
Study of prolonged administration of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2013 |
Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2013 |
Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Parathyroid Hormone; Phosphates; Polyamines; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors | 2013 |
Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
Topics: Administration, Oral; Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mastication; Middle Aged; Phosphorus; Renal Dialysis | 2013 |
The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Polyamines; Renal Dialysis; Risk Assessment; Sevelamer; Severity of Illness Index; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2013 |
Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome | 2014 |
Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Topics: Aged; Calcium; Calcium Carbonate; Chelating Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Topics: Adult; Aged; Chelating Agents; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Sevelamer; United States | 2014 |
Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chelating Agents; Double-Blind Method; Female; Humans; Hyperphosphatemia; Intention to Treat Analysis; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
Design and baseline characteristics of the LANDMARK study.
Topics: Aged; Biomarkers; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Clinical Protocols; Disease-Free Survival; Female; Humans; Hyperphosphatemia; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Calcium; Canada; Chronic Disease; Dose-Response Relationship, Drug; Europe; Female; Humans; Hyperphosphatemia; Israel; Kidney Diseases; Lanthanum; Male; Middle Aged; Outcome Assessment, Health Care; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome | 2008 |
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphorus; Renal Dialysis; Tablets; Time Factors; Treatment Outcome; United States | 2008 |
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Treatment Outcome | 2008 |
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Topics: Antacids; Calcium Carbonate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2008 |
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Chelating Agents; Chelation Therapy; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus, Dietary; Renal Dialysis; Survival Analysis; Time Factors | 2009 |
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Topics: Abdominal Pain; Adult; Aged; Calcium; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nausea; Parathyroid Hormone; Phosphates; Renal Dialysis; Treatment Outcome; Vomiting | 2010 |
Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Topics: Adult; Aged; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Young Adult | 2011 |
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Models, Economic; Phosphorus; Quality-Adjusted Life Years; Renal Dialysis; Time Factors; Treatment Outcome; Young Adult | 2011 |
Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Topics: Administration, Oral; Adult; Aged; Attitude of Health Personnel; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphates; Phosphorus; Physicians; Tablets; Treatment Outcome | 2011 |
Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Phosphorus Compounds; Phosphorus, Dietary; Reference Values; Single-Blind Method; Young Adult | 2012 |
Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.
Topics: Asian People; Calcium; Chelating Agents; Constipation; Cross-Over Studies; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Phosphates; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Treatment Outcome | 2012 |
Effects of phosphate binders in moderate CKD.
Topics: Acetates; Aged; Aged, 80 and over; Bone Density; Calcium Compounds; Chelating Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2012 |
Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Analysis of Variance; Calcium; Calcium Carbonate; Chelating Agents; Chi-Square Distribution; Cross-Over Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypercalcemia; Hyperphosphatemia; Isoenzymes; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase; Vitamin D | 2012 |
Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Topics: Adult; Calcium; Calcium Carbonate; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Phosphates; Prospective Studies; Republic of Korea | 2013 |
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
Topics: Adolescent; Adult; Aged; China; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Prevalence; Renal Insufficiency, Chronic; Risk Assessment; Treatment Outcome; Young Adult | 2013 |
Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Topics: Adult; Aged; Asian People; Calcium; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Dialysis | 2008 |
71 other study(ies) available for lanthanum and Hyperphosphatemia
| Article | Year |
|---|---|
Evaluation of cerium oxide as a phosphate binder using 5/6 nephrectomy model rat.
Topics: Animals; Cerium; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Nephrectomy; Phosphates; Phosphorus; Rats; Renal Insufficiency, Chronic | 2022 |
Lanthanum masquerading as foreign body ingestion in a critically ill patient with end-stage renal disease.
Topics: Critical Illness; Eating; Foreign Bodies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis | 2023 |
High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders.
Topics: Carbonates; Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Quality of Life; Tablets | 2023 |
A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.
Topics: Humans; Hyperphosphatemia; Intestinal Obstruction; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Tablets | 2023 |
[Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Rats, Wistar; Renal Dialysis; Swine; Swine, Miniature; Therapeutic Equivalency | 2019 |
Intratumoral inorganic phosphate deprivation: A new anticancer strategy?
Topics: Acetates; Animals; Antineoplastic Agents; Carcinogenesis; Chelating Agents; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease Progression; Hyperphosphatemia; Lanthanum; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Phosphates; Rabbits | 2020 |
Investigating coherent normalization and dosimetry for the
Topics: Bone and Bones; Child, Preschool; Fluorescence; Humans; Hyperphosphatemia; Lanthanum; Monte Carlo Method; Phantoms, Imaging; Radiation Dosage; Spectrometry, X-Ray Emission; X-Rays | 2020 |
Massive upper gastrointestinal bleeding due to gastric lanthanosis.
Topics: Gastrointestinal Hemorrhage; Gastroscopy; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Stomach Diseases | 2021 |
In Search of the Optimal Target for Phosphate Control: Episode 1.
Topics: Humans; Hyperphosphatemia; Lanthanum; Phosphates | 2021 |
Gastric lanthanosis (lanthanum deposition) in dialysis patients treated with lanthanum carbonate.
Topics: Adult; Aged; Aged, 80 and over; Female; Gastric Mucosa; Histiocytes; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Renal Dialysis | 2017 |
Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach.
Topics: Aged; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Retrospective Studies; Stomach | 2017 |
Correlation of lanthanum dosage with lanthanum deposition in the gastroduodenal mucosa of dialysis patients.
Topics: Aged; Dose-Response Relationship, Drug; Female; Gastric Mucosa; Histiocytes; Humans; Hyperphosphatemia; Intestinal Mucosa; Lanthanum; Male; Middle Aged; Renal Dialysis | 2017 |
Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
Topics: Calcium; Chelating Agents; Drug and Narcotic Control; Health Care Costs; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Medicare Part D; Needs Assessment; Phosphorus; Renal Dialysis; Sevelamer; United States | 2018 |
Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nutritional Status; Phosphates; Phosphorus; Propensity Score; Renal Dialysis; Treatment Outcome | 2019 |
Gastric lanthanum phosphate deposition masquerading as white globe appearance.
Topics: Aged; Biopsy; Gastric Mucosa; Humans; Hyperphosphatemia; Lanthanum; Male; Microscopy, Electron, Scanning | 2019 |
Nano-lanthanum hydroxide, a novel phosphate binder, for treating hyperphosphatemia: A preclinical study.
Topics: Animals; Drug Evaluation, Preclinical; Female; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mice; Nanoparticles; Phosphates; Rats; Rats, Wistar | 2019 |
Lanthanum phosphate binder-induced iron deficiency anaemia.
Topics: Aged; Anemia, Iron-Deficiency; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male | 2019 |
Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.
Topics: Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Niacinamide; Phosphates; Renal Insufficiency, Chronic | 2019 |
Pharmacobezoar in a patient on an oral phosphate binder.
Topics: Aged; Bezoars; Bronchi; Bronchoscopy; Foreign Bodies; Humans; Hyperphosphatemia; Intestinal Obstruction; Lanthanum; Male; Radiography; Rectal Diseases; Tablets | 2013 |
Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
Topics: Aged; Bone and Bones; Bone Diseases; Dose-Response Relationship, Drug; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats.
Topics: Animals; Chelating Agents; Diet; Disease Models, Animal; Extracellular Matrix; Fibroblast Growth Factors; Heart Ventricles; Hyperphosphatemia; Hypertrophy, Left Ventricular; Lanthanum; Male; Nephrectomy; Parathyroid Hormone; Phosphates; Rats, Sprague-Dawley; Uremia; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Hyperphosphatemia and phosphate binders: effectiveness and safety.
Topics: Calcium; Chelating Agents; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Hyperthyroidism; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Renal Insufficiency; Sevelamer; Vascular Calcification | 2014 |
Chewability testing in the development of a chewable tablet for hyperphosphatemia.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Ferric Compounds; Hardness; Hyperphosphatemia; Lanthanum; Mastication; Tablets | 2014 |
High phosphate feeding induced arterial medial calcification in uremic rats: roles of Lanthanum carbonate on protecting vasculature.
Topics: Animals; Calcinosis; Collagen Type II; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hyperphosphatemia; Integrin-Binding Sialoprotein; Lanthanum; Male; Osteocalcin; Phosphates; Phosphorus, Dietary; Rats; Transcription Factors; Tunica Media; Uremia | 2013 |
Optimal phosphate control: still an unmet need in chronic kidney disease patients.
Topics: Humans; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
Lanthanum carbonate prevents accelerated medial calcification in uremic rats: role of osteoclast-like activity.
Topics: Acid Phosphatase; Animals; Calcinosis; Cathepsin K; Core Binding Factor Alpha 1 Subunit; Enzyme-Linked Immunosorbent Assay; Hyperphosphatemia; Isoenzymes; Lanthanum; Osteocalcin; Osteoclasts; RANK Ligand; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Tartrate-Resistant Acid Phosphatase; Uremia | 2013 |
A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Topics: Acetates; Adult; Biomarkers; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Female; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Sevelamer; Time Factors; Treatment Outcome | 2014 |
REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain.
Topics: Aged; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Retrospective Studies; Spain; Treatment Outcome | 2014 |
Is granular formulation of lanthanum carbonate more effective than chewable tablets?
Topics: Adult; Aged; Chemistry, Pharmaceutical; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Tablets | 2014 |
Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
Topics: Adult; Aged; Aged, 80 and over; Chemistry, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Patient Preference; Phosphorus; Renal Dialysis; Surveys and Questionnaires; Tablets | 2014 |
Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Topics: Adult; Costs and Cost Analysis; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Retrospective Studies; Sevelamer; Tablets | 2014 |
Extensive lanthanum deposition in the gastric mucosa: the first histopathological report.
Topics: Adenocarcinoma; Breast Neoplasms; Female; Gastric Mucosa; Humans; Hyperphosphatemia; Lanthanum; Microscopy, Electron, Scanning; Middle Aged; Neoplasms, Second Primary; Renal Insufficiency, Chronic; Spectrometry, X-Ray Emission; Stomach Neoplasms | 2015 |
Tip-toeing toward the finish line.
Topics: Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Renal Dialysis | 2015 |
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.
Topics: Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Evaluation of intestinal phosphate binding to improve the safety profile of oral sodium phosphate bowel cleansing.
Topics: Acute Kidney Injury; Administration, Oral; Aluminum Hydroxide; Animals; Colonoscopy; Disease Models, Animal; Fibroblast Growth Factor-23; Hyperphosphatemia; Kidney Function Tests; Lanthanum; Male; Phosphates; Rats; Rats, Wistar | 2015 |
Unexpected action of lanthanum carbonate.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Renal Insufficiency, Chronic | 2015 |
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Topics: Acidosis; Bicarbonates; Canada; Chelating Agents; Disease Progression; Drug Monitoring; Female; Humans; Hyperphosphatemia; Kidney Function Tests; Lanthanum; Male; Middle Aged; Nutritional Status; Patient Acuity; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2015 |
Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Topics: Bone and Bones; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Renal Dialysis; Time Factors | 2015 |
Specific Accumulation of Lanthanum Carbonate in the Gastric Mucosal Histiocytes in a Dialysis Patient.
Topics: Biopsy; Carcinoma, Renal Cell; Gastroscopy; Histiocytes; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Kidney Neoplasms; Lanthanum; Male; Microscopy, Electron, Scanning; Middle Aged; Nephrectomy; Renal Dialysis; Stomach Diseases; Tomography, X-Ray Computed | 2015 |
White Gastric Mucosa in a Dialysis Patient.
Topics: Administration, Oral; Aged; Biopsy; Chelating Agents; Endoscopy, Digestive System; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Microscopy, Electron, Scanning; Renal Dialysis; Spectrometry, X-Ray Emission | 2016 |
Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Topics: Administration, Oral; Animals; Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Hyperphosphatemia; Lanthanum; Male; Phosphates; Rats; Rats, Sprague-Dawley; Sevelamer; Sucrose | 2016 |
Lanthanum phosphate deposition in the duodenum.
Topics: Aged; Duodenum; Endoscopy, Gastrointestinal; Gastric Mucosa; Humans; Hyperphosphatemia; Intestinal Mucosa; Lanthanum; Male; Microscopy, Electron, Scanning; Renal Dialysis | 2017 |
Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract.
Topics: Adult; Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Upper Gastrointestinal Tract | 2017 |
Lanthanum Deposition in the Stomach: Usefulness of Scanning Electron Microscopy for Its Detection.
Topics: Aged; Endoscopy, Digestive System; Female; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Microscopy, Electron, Scanning | 2017 |
Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
Topics: Animals; Arteries; Bone and Bones; Calcinosis; Chondrogenesis; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Osteogenesis; Phosphates; Rats; Rats, Wistar; Vascular Diseases | 2009 |
An unusual abdominal radiograph.
Topics: Abdominal Pain; Colon; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphate-Binding Proteins; Radiography | 2009 |
[Acute abdominal pain in a 70-year-old patient on hemodialysis].
Topics: Abdominal Pain; Aged; Colectomy; Colon; Diabetic Nephropathies; Diagnosis, Differential; Foreign Bodies; Humans; Hyperphosphatemia; Ischemia; Kidney Failure, Chronic; Lactic Acid; Lanthanum; Male; Mastication; Radiography; Renal Dialysis; Tablets | 2009 |
Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Topics: Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Treatment Outcome | 2010 |
[Radiology image of lanthanum carbonate].
Topics: Abdominal Pain; Artifacts; Chelating Agents; Chelation Therapy; Colon; Diabetic Nephropathies; Diagnosis, Differential; Diverticulitis, Colonic; Diverticulosis, Colonic; Fever; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Tomography, X-Ray Computed | 2010 |
Tissue accumulation of lanthanum as compared to aluminum in rats with chronic renal failure--possible harmful effects after long-term exposure.
Topics: Aluminum; Aluminum Hydroxide; Animals; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Liver; Male; Organ Size; Rats; Rats, Sprague-Dawley | 2010 |
Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis.
Topics: Aged; Artifacts; Diagnosis, Differential; Foreign Bodies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Renal Dialysis; Tomography, X-Ray Computed | 2010 |
[Intestinal pseudo-occlusion due to lanthanum carbonate].
Topics: Aged; Chelating Agents; Chelation Therapy; Chronic Kidney Disease-Mineral and Bone Disorder; Colonic Diseases; Humans; Hyperphosphatemia; Intestinal Pseudo-Obstruction; Ischemia; Kidney; Kidney Failure, Chronic; Lanthanum; Laparotomy; Male; Phosphates; Radiography; Renal Dialysis | 2010 |
Christmas lights in the gastrointestinal tract.
Topics: Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Radiography, Abdominal | 2010 |
Overestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney disease.
Topics: Absorptiometry, Photon; Bone Density; Diagnostic Errors; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis | 2010 |
Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
Topics: Aged; Chelating Agents; Dyspepsia; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphates; Prospective Studies; Renal Dialysis | 2012 |
Pharmacology of the phosphate binder, lanthanum carbonate.
Topics: Aluminum Hydroxide; Animals; Calcium; Calcium Carbonate; Chelating Agents; Dogs; Drug Evaluation, Preclinical; Feces; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mice; Phosphates; Phosphorus Radioisotopes; Polyamines; Rats; Rats, Sprague-Dawley; Sevelamer | 2011 |
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
Topics: Aluminum; Bone Diseases; Chelating Agents; Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Polyamines; Renal Dialysis; Sevelamer | 2011 |
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
Topics: Adult; Aged; Antacids; Calcium; Calcium Carbonate; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome; Young Adult | 2012 |
Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Topics: Adult; Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cost Savings; Health Care Costs; Hemodialysis Solutions; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Technology Assessment, Biomedical | 2011 |
CKD-mineral and bone disorder: core curriculum 2011.
Topics: Bone Diseases; Calcinosis; Calciphylaxis; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Lanthanum; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2011 |
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Topics: Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Cross-Over Studies; Databases, Factual; Economics, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Polyamines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Sevelamer; United States | 2011 |
Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Topics: Aged; Chelating Agents; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Polyamines; Renal Dialysis; Sevelamer | 2011 |
Pre-existing oral contrast from lanthanum carbonate: a confounding factor in CT mesenteric angiography.
Topics: Administration, Oral; Aged; Angiography; Contrast Media; Gastrointestinal Hemorrhage; Humans; Hyperphosphatemia; Lanthanum; Male; Mesenteric Arteries; Tomography, X-Ray Computed | 2012 |
Lanthanum carbonate and peritoneal catheter dysfunction.
Topics: Catheters; Chelating Agents; Constipation; Equipment Failure; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Male; Middle Aged; Peritoneal Dialysis; Postoperative Complications; Primary Graft Dysfunction; Radiography | 2012 |
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Topics: Canada; Chelating Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Follow-Up Studies; Hospitalization; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Markov Chains; Models, Economic; Polyamines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Survival Rate; Treatment Outcome | 2012 |
Phosphate binders in CKD: bad news or good news?
Topics: Acetates; Calcium Compounds; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Unusual image of lanthanum carbonate in the abdominal radiograph.
Topics: Abdominal Pain; Aged; Appendix; Colon; Diarrhea; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Radiography | 2012 |
Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
Topics: Adult; Diabetic Nephropathies; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Multivariate Analysis; Nutritional Status; Parathyroid Hormone; Peritoneal Dialysis; Phosphates; Retrospective Studies | 2012 |
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
Topics: Acetates; Blood Vessels; Calcinosis; Calcium Compounds; Chelating Agents; Disease Progression; Humans; Hyperphosphatemia; Lanthanum; Phosphate-Binding Proteins; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Topics: Calcinosis; Chelating Agents; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2007 |
[Radiographic characteristics of lanthanum carbonate absorption].
Topics: Aged; Chelating Agents; Female; Humans; Hyperphosphatemia; Intestinal Absorption; Intestinal Diseases; Kidney Failure, Chronic; Lanthanum; Radiography | 2008 |